Loading patent…
AssigneeWake Forest University Health Sciences
InventorMartha A Alexander-Miller
Estimating the term…
An isolated or recombinant aminopeptidase N (pepN) polypeptide having inflammatory cytokine production and cytolysis inhibiting activity is provided. A method of inhibiting inflammatory cytokine production and cytolysis in a subject in need thereof is also provided, comprising administering to the subject an inflammatory cytokine production and cytolysis inhibiting amount of the isolated or recombinant pneumococcal pepN polypeptide. A method of treating a disease, disorder, or condition characterized by or associated with undesirable inflammatory cytokine production and cytolysis in a subject in need thereof is also provided, comprising administering to the subject a therapeutically effective amount of an isolated or recombinant pepN polypeptide. A method of treating pneumococcal infection in a subject in need thereof is also provided comprising administering to the subject a therapeutically effective amount of an anti-pepN polypeptide inhibitory agent.
An isolated or recombinant aminopeptidase N (pepN) polypeptide, wherein the isolated or recombinant pepN polypeptide comprises the amino acid sequence of SEQ ID NO:1 or a functional variant thereof, wherein the functional variant thereof has inflammatory cytokine production and cytolysis inhibiting activity and comprises an amino acid sequence at least 80% identical to the amino acid sequence of SEQ ID NO:1.
A method of inhibiting inflammatory cytokine production and cytolysis in a subject in need thereof, the method comprising administering to the subject an inflammatory cytokine production and cytolysis inhibiting amount of an isolated or recombinant aminopeptidase N (pepN) polypeptide, wherein the isolated or recombinant pepN polypeptide comprises the amino acid sequence of SEQ ID NO:1 or a functional variant thereof, wherein the functional variant thereof has inflammatory cytokine production and cytolysis inhibiting activity and comprises an amino acid sequence at least 80% identical to the amino acid sequence of SEQ ID NO:
13-21. (canceled)
A method of treating pneumococcal infection in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an anti aminopeptidase N (pepN) polypeptide inhibitory agent, wherein the anti-pepN polypeptide inhibitory agent is an anti-pepN polypeptide antibody or antigen-binding fragment thereof, a small molecule pepN polypeptide inhibitor, an RNA or DNA aptamer that binds or physically interacts with a pepN polypeptide, a soluble pepN polypeptide receptor, a pepN polypeptide specific antisense molecule, or a pepN polypeptide specific siRNA molecule.
Dependencies are inferred from the claim text.